Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.50 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 3/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4826412 | 0.86 | ESR1 (0.55) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL1358515 | 0.83 | ESR1 (0.63) | ESR1ESR2ENPP3ENPP1PSMB1 | |
| SCHEMBL5706416 | 0.80 | ENPP3 (0.52) | ESR1ESR2ENPP3ENPP1PSMB1 | |
| SCHEMBL5826407 | 0.80 | ESR1 (0.55) | ESR1ESR2ENPP3ENPP1PSMB1 | |
| SCHEMBL1360090 | 0.80 | ESR1 (0.63) | ESR1ESR2KCNH2PSMB1PSMB5 | |
| SCHEMBL1359326 | 0.80 | ESR1 (0.63) | ESR1ESR2KCNH2PSMB1PSMB5 | |
| SCHEMBL4931321 | 0.79 | ESR1 (0.50) | ESR1ESR2ENPP3ENPP1STS | |
| SCHEMBL4924889 | 0.79 | ESR1 (0.54) | ESR1ESR2ENPP3ENPP1PSMB1 | |
| SCHEMBL1358420 | 0.78 | ESR1 (0.54) | ESR1ESR2ENPP3ENPP1STS | |
| SCHEMBL3122366 | 0.78 | ESR1 (0.63) | ESR1ESR2ENPP3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221163-A1 | Selective Estrogen Receptor Modulators | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221163-A1 | Selective Estrogen Receptor Modulators | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885ENPP3 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.